The Food and Drug Administration has concluded several tests that found its regulatory framework is capable of handling nanotech products, said Celia Cruz, a senior reviewer at the agency's Center for Drug Evaluation and Research. "Our risk management exercise determined that our current regulatory review processes indeed can adequately protect the public from potential risks associated with the use of nanomaterials in drug products," Cruz said. There is still room for improvement, including new training and research, Julian Hattem writes.

Related Summaries